Market News How it works Learn FAQ
| TGL 0.2897 30.79% | SRTM 0.6164 43.25% | NU 11.845 -21.87% | GCDT 0.1604 -8.92% | EWZ 31.98 -24.91% | NWGL 0.0808 -1.46% | SHFS 0.1254 -5.29% | RBNE 0.183 -3.68% | CLRO 4.2705 31.40% | SPRC 1.635 50.00% | SOXL 87.29 4.46% | BBD 2.9088 -28.53% | VBIO 0.785 -16.49% | RENT 2.85 23.91% | ITUB 7.63 -21.10% | PBR 21.675 -17.14% | SOXS 50.2 -4.31% | TSLL 10.68 9.43% | SPCX 147.12 -0.25% | XP 14.42 -52.58% | XXII 0.1032 -47.80% | GPUS 0.1583 -6.28% | WFF 0.0741 -7.38% | KORU 10.59 0.09% | CRWV 52.0841 -3.97% | IREN 24.13 -3.11% | STNE 7.83 -31.79% | SQQQ 39.02 -1.66% | PRSO 0.35 -7.51% | NOK 8.44 3.69% | INTR 4.751 -33.92% | MYND 0.2219 -7.54% | TQQQ 67.37 1.63% | INTC 88.11 1.32% | VALE 12.27 -1.05% | NVDA 214.88 1.86% | TSLA 389.99 4.77% | VZ 43.45 -2.71% | IBIT 44.9769 -2.14% | WORX 2.2101 0.92% | YMAT 2.25 9.76% | AZTR 0.9102 1,173.01% | JBLU 2.4312 -7.38% | STLA 4.105 1.11% | WULF 11.36 0.35% | T 21.075 0.69% | IRE 2.9 -6.15% | PAGS 8.6 -24.83% | META 631.35 -1.75% | NBIS 151.07 -4.83%
BBBridgeBio Oncology Therapeutics Inc. logo

BridgeBio Oncology Therapeutics Inc. (BBOT)

NASDAQ Global Market · Currency in USD
$2.65 ▼ -0.02 (-0.56%)
As of Oct 26, 10:17 AM ET. Market open.

Summary

Previous Close
$2.66
Open
$2.65
Day's Range
$2.61 – $2.66
52 Week Range
$2.60 – $14.87
Volume
27,640
Avg. Volume
510,010
Market Cap
$212.06M
Beta (5Y Monthly)
0.39
PE Ratio (TTM)
--
EPS (TTM)
-$2,274.89
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$19.00

Profile: BridgeBio Oncology Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
88
CEO
Pedro J. Beltran
Website
bbotx.com

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.69
DateEst.Actual
Aug 11, 2026-$0.57-$0.71Miss
May 12, 2026-$0.51-$0.48Beat
Mar 5, 2026-$0.63-$0.49Beat
Nov 12, 2025-$0.38-$1.03Miss
Aug 1, 2025-$42.45-$50.35Miss
May 15, 2025–-$52.15

Analyst view

Consensus price target
$19.00 ▲ +618.3%
Range $15.00 – $22.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on BBOT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.